Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about EXEL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Cabozantinib FDA approved Nov 2012 · Cometriq |
Medullary Thyroid Cancer | Phase 4 · NCT01896479 | Active not recruiting |
| Zanzalintinib (XL092) | Pancreatic Neuroendocrine Tumor (pNET) | Phase 2/3 · NCT06943755 | Recruiting |
| Sunitinib | Renal Cell Carcinoma | Phase 3 · NCT03141177 | Completed |
| Berahyaluronidase Alfa and Pembrolizumab | Colorectal Cancer | Phase 3 · NCT07750158 | Recruiting |
| Tegavivint | Hepatocellular Carcinoma (HCC) | Phase 1/2 · NCT07878689 | Not yet recruiting |
| Regorafinib | Cancer | Phase 2 · NCT03899155 | Recruiting |
| Nab-paclitaxel | Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 · NCT07845786 | Recruiting |
| USP1 Inhibitor ISM3091 | Advanced Solid Tumor | Phase 1 · NCT05932862 | Active not recruiting |
| Anti-5T4/MMAE Antibody-drug Conjugate XB010 | Locally Advanced or Metastatic Solid Tumors | Phase 1 · NCT06545331 | Recruiting |
| DDI Probe Cocktail | Renal Cell Carcinoma (RCC) | Phase 1 · NCT05176483 | Recruiting |
Also used in these trials (approved or third-party drugs, not EXEL's own candidates): Abiraterone Acetate, Sunitinib Malate, Prednisone, Nivolumab, Ipilimumab, Everolimus, Enzalutamide, Atezolizumab, Belzutifan, Abemaciclib, Tremelimumab, Trametinib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
EXEL holds $1.5B in cash and short-term investments (as of Oct 2, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when EXEL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Dapice Joshua J. | 5%+ holder (13D) | 15,709,500 | 6.44% | 2026-01-01 |
| Farallon Capital Management, L.L.C. | Institution (13G, 5%+) | 14,694,910 | 6.02% | 2026-11-09 |
| Vanguard Capital Management | Institution (13G, 5%+) | 13,233,247 | 5.42% | 2026-03-31 |
| Michael Morrissey President and CEO, Director |
Insider | 3,384,063 | 1.39% | 2026-05-15 |
| Stelios Papadopoulos Director |
Insider | 1,197,595 | 0.49% | 2026-05-27 |
| Christopher J. Senner EVP and CFO |
Insider | 955,040 | 0.39% | 2026-05-15 |
| Dana Aftab EVP, Research and Development |
Insider | 600,576 | 0.25% | 2026-05-26 |
| Patrick J. Haley EVP, Commercial |
Insider | 357,638 | 0.15% | 2026-05-20 |
| Jack L Wyszomierski Director |
Insider | 284,384 | 0.12% | 2026-06-01 |
| George Poste Director |
Insider | 127,199 | 0.05% | 2026-05-27 |
| Brenda Hefti SVP and General Counsel |
Insider | 112,289 | 0.05% | 2026-05-15 |
| Maria C Freire Director |
Insider | 109,186 | 0.04% | 2026-05-27 |
Share count 244,010,895 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EXEL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →